Type 2 Diabetes Mellitus Clinical Trial
Official title:
The Acute Effects of Triacylglycerol Structure of Dietary Fats on Gut Hormones and Haemostatic Markers in Subjects With Type 2 Diabetes Mellitus
| Verified date | October 2015 |
| Source | Malaysia Palm Oil Board |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | Malaysia: Ministry of Health |
| Study type | Interventional |
Type 2 diabetes mellitus (T2DM) is a chronic disorder determined by lifestyle and genes. It is associated with chronic hyperglycaemia along with other metabolic abnormalities. It is also one of the risk factors for cardiovascular disease (CVD). This disease is due to insulin resistance and/or deficiency as well as increased hepatic glucose output. According to the Third National Health and Morbidity Survey (3rd NHMS), the prevalence of T2DM for adults aged 30 years and above is 14.9%, increased by almost 80% from 1996 to 2006. Dietary composition may affect insulin sensitivity, postprandial triacylglycerol concentration and the risk of T2DM. The role of dietary fats in T2DM is of particular interest and has been clinically studied for many decades. The type of fat we ingest every day consists of different types of fatty acids and different degree of saturation, which in turn influence glucose metabolism by altering cell membrane function, enzyme activity, insulin signalling and gene expression. Previous studies demonstrated that interesterification of dietary fat alter postprandial lipaemia. Saturated fat such as palm olein has been reported to display lower postprandial lipaemia after interesterification. Changing the structure of triacylglycerol (TAG) alters the physical properties of dietary fat which affects digestibility, metabolism and atherogenicity. A recent study conducted by Sanders and co-workers demonstrated reduced levels of plasma glucose-dependent insulinotropic polypeptide (GIP) following both the lard and interesterified palm olein (IPO) compared with the palm olein (PO) and high oleic sunflower oil (HOS) diets in healthy subjects. The GIP and glucagon-like peptide-1 (GLP-1) are major players in the modulation of postprandial insulin secretion by the pancreas. Although GIP secretion in response to meals is normal in patients with Type 2 diabetes mellitus (T2DM), GIP induced secretion of insulin is defective in diabetes. This is observed to be predominantly a defective stimulation of the late phase of insulin response (20-120 minutes). The effect of IPO on GIP may be exaggerated in T2DM patients with impaired insulin sensitivity. Hence, IPO may change the concentrations of gut hormones, postprandial lipaemia, insulinaemic response and CVD related haemostatic markers.
| Status | Completed |
| Enrollment | 23 |
| Est. completion date | March 2014 |
| Est. primary completion date | July 2013 |
| Accepts healthy volunteers | No |
| Gender | Both |
| Age group | 30 Years to 60 Years |
| Eligibility |
Inclusion Criteria: 1. Mild T2DM individuals not planned for medical intervention - 7.0 mmol/L = fasting glucose = 11.1 mmol/L - 6.5% = HbA1c = 9.0% - Not using antihypertensive, lipid lowering, insulin/glucose modulating medication 2. Mild T2DM individuals currently on medical intervention - Fasting glucose = 11.1 mmol/L - HbA1c = 9.0% - Using antihypertensive, lipid lowering or glucose modulating medication 3. Malaysian male or female with T2DM aged between 30 to 60 years old 4. Not using insulin 5. Not having any complications of diabetes 6. No medical history of myocardial infarction, angina, thrombosis, stroke or cancer 7. Haemoglobin levels for females = 11.5 gm/dl and males = 12.5 gm/dl 8. Serum ferritin > 15 µg/l at commencement of study Exclusion Criteria: 1. Medical history of myocardial infarction, angina, thrombosis, stroke or cancer 2. Underweight (BMI < 18.5 kg/m²) 3. Using insulin 4. Total cholesterol > 7.0 mmol/L 5. Abnormal liver function, renal function and haematology 6. Hypersensitive towards heparin 7. Gastric or lactose intolerance 8. Smoker 9. Pregnancy and lactating 10. Taking alcohol 11. Taking alcohol 12. Haemoglobin levels for females = 11.5 gm/dl and males = 12.5 gm/dl 13. Serum ferritin < 15 µg/l at commencement of study |
Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention
| Country | Name | City | State |
|---|---|---|---|
| Malaysia | Hulu Langat District Health Office | Kajang | Selangor |
| Malaysia | Malaysian Palm Oil Board (MPOB) | Kajang | Selangor |
| Malaysia | Sepang District Health Office | Sepang | Selangor |
| Malaysia | Universiti Putra Malaysia | Serdang | Selangor |
| Malaysia | Selangor State Health Office | Shah Alam | Selangor |
| Lead Sponsor | Collaborator |
|---|---|
| Malaysia Palm Oil Board | Ministry of Health, Malaysia, Universiti Putra Malaysia |
Malaysia,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | 6-hour postprandial changes from fasting in glucose-dependent insulinotropic polypeptide (GIP) | To determine the postprandial changes of GIP. | 0, 15, 30, 60, 90, 120 min, 3, 4, 5, 6 hour | No |
| Secondary | 6-hour postprandial changes from fasting in gut hormones | To determine the postprandial changes of ghrelin, glucagon-like peptide-1 (GLP-1), peptide YY (PYY) and cholecystokinin (CCK). | 0, 15, 30, 60, 90, 120 min, 3, 4, 5, 6 h | No |
| Secondary | 6-hour postprandial changes from fasting in insulinaemic response | To determine the postprandial changes of glucose, insulin, C-peptide and non-esterified fatty acid (NEFA) | 0, 15, 30, 60, 90, 120 min, 3, 4, 5, 6 hour | No |
| Secondary | 6-hour postprandial changes from fasting in lipaemia | To determine the postprandial changes of triacylglycerol (TAG) and apolipoprotein B48 (apoB48). To compare lipoprotein lipase (LPL) activity, chylomicron fatty acid composition and plasma fatty acid (PFA) composition across meals. |
0, 1, 2, 3, 4, 5, 6 hour for TAG and apoB48; 6 hour postheparin for LPL; pooled 3, 4, 5 hour for chylomicron and PFA | No |
| Secondary | 6-hour postprandial changes from fasting in haemostatic response | To determine the postprandial changes of factor FVII activation (FVIIa), plasminogen activator inhibitor-1 (PAI-1)and D-dimer. To compare pulse wave analysis (PWA) across meals. |
0, 2, 4, 6 hour for FVIIa, PAI-1 and D-dimer; 0, 4 hour for PWA | No |
| Secondary | 6-hour changes from fasting hunger rating using visual analogue scale (VAS) | To determine the changes in hunger rating and food satiety | 0, 15, 30, 60, 90, 120 min, 3, 4, 5, 6 hour | No |
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT02771093 -
An Exploratory Study of the Effects of Trelagliptin and Alogliptin on Glucose Variability in Patients With Type 2 Diabetes Mellitus
|
Phase 4 | |
| Completed |
NCT02545842 -
Assessment Study of Three Different Fasting Plasma Glucose Targets in Chinese Patients With Type 2 Diabetes Mellitus (BEYOND III/FPG GOAL)
|
Phase 4 | |
| Recruiting |
NCT03436212 -
Real-Life Home Glucose Monitoring Over 14 Days in T2D Patients With Intensified Therapy Using Insulin Pump.
|
N/A | |
| Completed |
NCT03244800 -
A Study to Investigate Different Doses of 0382 in Overweight and Obese Subjects With Type 2 Diabetes Mellitus.
|
Phase 2 | |
| Completed |
NCT03960424 -
Diabetes Management Program for Hispanic/Latino
|
N/A | |
| Withdrawn |
NCT02769091 -
A Study in Adult Patients With Nonalcoholic Steatohepatitis Who Also Have Type 2 Diabetes
|
Phase 2 | |
| Recruiting |
NCT06065540 -
A Research Study to See How Well CagriSema Compared to Semaglutide, Cagrilintide and Placebo Lowers Blood Sugar and Body Weight in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor
|
Phase 3 | |
| Recruiting |
NCT05008276 -
Puberty, Diabetes, and the Kidneys, When Eustress Becomes Distress (PANTHER Study)
|
||
| Completed |
NCT04091373 -
A Study Investigating the Pharmacokinetics of a Single Dose Administration of Cotadutide
|
Phase 1 | |
| Completed |
NCT03296800 -
Study to Evaluate Effects of Probenecid, Rifampin and Verapamil on Bexagliflozin in Healthy Subjects
|
Phase 1 | |
| Recruiting |
NCT06212778 -
Relationship Between Nutritional Status, Hand Grip Strength, and Fatigue in Hospitalized Older Adults With Type 2 Diabetes Mellitus.
|
||
| Completed |
NCT05979519 -
Fresh Carts for Mom's to Improve Food Security and Glucose Management
|
N/A | |
| Recruiting |
NCT05579314 -
XW014 in Healthy Subjects and Patients With Type 2 Diabetes Mellitus (T2DM)
|
Phase 1 | |
| Completed |
NCT03859934 -
Metabolic Effects of Melatonin Treatment
|
Phase 1 | |
| Terminated |
NCT03684642 -
Efficacy and Safety of Efpeglenatide Versus Dulaglutide in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin
|
Phase 3 | |
| Completed |
NCT03248401 -
Effect of Cilostazol on Carotid Atherosclerosis Estimated by 3D Ultrasound in Patients With Type 2 Diabetes
|
Phase 4 | |
| Completed |
NCT03644134 -
A Personalized Intervention to Manage Physiological Stress and Improve Sleep Patterns
|
N/A | |
| Completed |
NCT05295160 -
Fasting-Associated Immune-metabolic Remission of Diabetes
|
N/A | |
| Completed |
NCT02836873 -
Safety and Efficacy of Bexagliflozin in Type 2 Diabetes Mellitus Patients With Moderate Renal Impairment
|
Phase 3 | |
| Completed |
NCT02226003 -
Efficacy and Safety of Ertugliflozin (MK-8835/PF-04971729) With Sitagliptin in the Treatment of Participants With Type 2 Diabetes Mellitus (T2DM) With Inadequate Glycemic Control on Diet and Exercise (MK-8835-017)
|
Phase 3 |